AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06696378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 6 mg
Description: wo capsules per day; Each capsule includes 3mg Melatonin Nutrifoods® Laboratories, Barcelona, Spain) by the Magistral Formulation Laboratory of a Pharmacy (Soria, Spain), following the rules of the Royal Spanish Pharmacopoeia (Ministry of Health, Government of Spain). Melatonin has a technical data sheet that guarantees its composition and purity (Reference No.: DIE-134).
Study NCT05995119 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
Description: The subjects were administered either the test (TAH3311 5 mg ODF as Treatment T1) or reference (ELIQUIS® 5 mg oral tablet as Treatment R1) product at 30 minutes following the start of a standardized high-fat, high-calorie breakfast that was preceded by an overnight fast of at least 10 hours. In the other two study periods, the subjects were administered either the test (Treatment T2) or reference (Treatment R2) product following an overnight fast of at least 10 hours. The subjects received the test and reference products in accordance with a four-sequence randomization schedule. There was a washout period of 5 days between the dosing days of any two consecutive periods.
Study NCT06393036 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: The intervention in this study involves the use of Continuous Positive Airway Pressure (CPAP) treatment. Although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, CPAP, present in the observational cohort. CPAP is a commonly used therapy for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. The principle of CPAP treatment lies in maintaining a constant airway pressure during sleep to prevent the collapse of the upper airway and ensure unobstructed breathing. The patient wears a mask connected to a CPAP machine, which generates a steady stream of air to provide the necessary pressure.
Study NCT05667194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH617
Description: KH617 is s freeze-dried powder injection
Study NCT06696378 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Melatonin tablets to ensure blinding.
Study NCT06707935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Descriptive social norm nudges
Description: A set of messages with descriptive social norm nudges sent to participants.
Study NCT06707935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pictorial social norm nudges
Description: A set of messages with pictorial social norm nudges sent to participants.
Study NCT06707935 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Service as usual
Description: Traditional mental health education information disseminated to participants.
Study NCT06711224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention for adolscents with ADHD
Description: The aim of the digital intervention is to promote coping of ADHD. The intervention has a duration of 6 weeks and will be delivered as a mobile app including weekly phone calls from a therapist. The intervention includes text, interactive exercises, animations, and coping skills. The themes of the intervention includes psychoeducation on ADHD, healthy habits (sleep, exercise, food), social skills, and emotion regulation. The adolescents have the possibility to choose some of the themes they want to work on during the intervention.
Study NCT06707675 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: The patients' demographic information, weight and height measurements, occupational activities and desk work time, daily screen usage time, pain intensity (with VAS), cervical joint range of motion examination, pain threshold (with pressure algometer), functional status (with Neck Pain Disability Scale), sleep quality (with Pittsburgh Sleep Quality Scale), anxiety and depression symptoms (with Beck Depression Inventory), cognitive aspects of pain (with Pain Catastrophizing Scale) will be evaluated. The patients' chronotype preferences will be evaluated with Morningness Eveningness Questionnaire.
Study NCT06708832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMBA ingestion
Description: Ingestion of 2 SIMBA capsules at the same time and their excretion.
Study NCT06712173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linperlisib and SHR2554
Description: Linperlisib doses were preset at 40mg QD and 60mg QD, while SHR2554 doses were preset at 150mg BID, 200mg BID, and 300mg BID, forming six dose groups in total.
Study NCT06711471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
Description: Patients enrolled in this study will receive trifluridine/tipiracil in combination with bevacizumab and camrelizumab, with a treatment cycle of 14 days, until disease progression, death, intolerable toxicity, or other criteria for discontinuation of study treatment as specified in the protocol (whichever occurs first).
Study NCT06713694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral therapy
Description: The treatment will consist of eight weekly sessions, each lasting one hour. The first session will focus on the rationale of cognitive behavioral therapy, i.e. the influence of (irrational or dysfunctional) cognitions and attitudes on (restrictive) feelings and behaviors. Additionally, goal setting will be initiated. Since patients may have a wide diversity of psychiatric problems (i.e. PTSD, anxiety disorders and depression), the treatment manual will encompass five optional modules for the therapist that focus on each of these disorders (i.e. exposure based for anxiety and PTSD, behavioral activation for depression). The subsequent sessions (2-6) will target teaching the patient to identify and challenge dysfunctional cognitions and attitudes related to IBD. Each session will address specific illness-related cognitions. If possible, dysfunctional cognitions and attitudes will be replaced by helpful cognitions and attitudes.
Study NCT06713694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait first, then cognitive-behavioral therapy
Description: participants assigned to the waiting-list control condition will wait 3.5 months before they are treated with CBT. This period corresponds to the duration of the CBT intervention and follow-up assessment of the experimental group. After this 3.5 month waiting period the participants in the waiting-list control condition will be asked to complete a follow-up after waiting/baseline before CBT assessment before starting treatment.
Study NCT06713772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
Description: Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA
Study NCT06713772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steri-StripsTM (3M, St. Paul, Minnesota, USA
Description: Steri-StripsTM (3M, St. Paul, Minnesota, USA
Study NCT06713772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
Description: Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany
Study NCT04539041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antisense oligonucleotide
Description: solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
Study NCT04539041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for each dose level
Study NCT06713148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDOV-SAFETM
Description: Each patient received intratumoral injection on the first day, 14 days as a course of treatment, and the follow-up investigator decided whether to continue the second (D14) and third (D28) course of administration according to the comprehensive evaluation of the subjects' conditions
Study NCT06711705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.
Study NCT04960280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ©VoqX stethoscope
Description: Computerized auscultation detects both infrasound and audible sounds and is capable of amplifying auscultated sounds by a factor of thirty.
Study NCT06360718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Who is Luke Eemia? Storybook
Description: Parents in this group will receive the Who is Luke Eemia? storybook, and will receive guidance from the child life specialist on how to utilize the storybook with their school-aged child. Parents in this study will complete surveys at three timepoints, these surveys include: (1) Comfort Survey (prior to child life intervention), (2) Discharge Survey and (3) Storybook Assessment survey to review the parent's impression of the storybook intervention tool (at the time of discharge, or about 1 week following the child life intervention), and the (4) Parenting Stress Index -4-Short Form (at baseline, at the time of the discharge survey, and about 3.5 months later).
Study NCT04286555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH4D diet
Description: DASH stands for Dietary Approaches to Stop Hypertension. The DASH diet is a healthy dieter that lowers blood pressure. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages. The DASH4D dietary pattern is a version of the DASH diet that is lower in carbohydrate.
Study NCT04286555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: comparison diet
Description: The comparison dietary pattern is based on a typical American diet, with macronutrient distributions generally at the average of typical US intake, and micronutrient targets generally near the 25th percentile of usual US intake (with the exception of sodium).
Study NCT04286555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: comparison diet
Description: The comparison dietary pattern is based on a typical American diet, with macronutrient distributions generally at the average of typical US intake, and micronutrient targets generally near the 25th percentile of usual US intake (with the exception of sodium).
Study NCT04693377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04693377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04286555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: higher sodium
Description: 3700 mg/day sodium (at the 2000 kilocalorie level)
Study NCT04693377 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy
Study NCT04693377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy
Study NCT05884528 — intervention group
Intervention type: BIOLOGICAL
Intervention: CC BoNT/A
Description: Complex-containing BotulinumtoxinA (BoNT/A) formulations
Study NCT05884528 — intervention group
Intervention type: BIOLOGICAL
Intervention: CF BoNT/A
Description: Complex-free BotulinumtoxinA (BoNT/A) formulation
Study NCT05884528 — intervention group
Intervention type: BIOLOGICAL
Intervention: CF to CC BoNT/A
Description: Switch from complex-free to complex-containing BoNT/A formulations
Study NCT04286555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: higher sodium
Description: 3700 mg/day sodium (at the 2000 kilocalorie level)
Study NCT05884528 — intervention group
Intervention type: BIOLOGICAL
Intervention: CC to CF BoNT/A
Description: Switch from complex-containing to complex-free BoNT/A formulations
Study NCT05772156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Description: Methylergonovine 200mcg Intramuscular (IM)
Study NCT04234360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 days of systemic corticotherapy (prednisone)
Description: Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
Study NCT04234360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5 days of placebo
Description: Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
Study NCT06021288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effluent dose of CRRT
Description: The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
Study NCT05772156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching saline placebo
Study NCT04020263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan 2.5 MG/ML Injectable Solution
Description: Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
Study NCT04020263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
Study NCT05989477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At-home Breast Oncology care Delivered with E-health solutions - ABODE
Description: The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.
Study NCT06303752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRC injection
Description: Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
Study NCT06303752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADRC001 injection
Description: Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
Study NCT04286555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower sodium
Description: 1500 mg/day sodium (at the 2000 kilocalorie level)
Study NCT06021288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effluent dose of CRRT
Description: The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
Study NCT06508723 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental implant placement
Description: The same routine implant placement protocol will be applied to both study groups with different surfaces and will be placed in the bone. After local anesthesia, a full-thickness flap will be raised. The implant socket will be created according to the protocol recommended by the company and all implants will be placed in the socket with a torque force of 35 N and the implants will be placed. Once bleeding control is achieved, the flap will be closed primarily. Healing caps will be installed after 3 months. After waiting for wound healing, prosthetic restoration will be performed.
Study NCT05397106 — intervention group
Intervention type: DEVICE
Intervention: CODMAN CERTAS Plus Programmable Valve
Description: Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
Study NCT06494553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical stabilization exercises
Description: Neck stabilization exercises included the following: Chin tuck, cervical extension, Shoulder shrugs, Shoulder rolls, Scapular retraction
Study NCT06494553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Description: The Chattanooga Intelect ultrasound made in America. Year of production: 2013. It was clinically proven to provide the best possible treatment outcomes by utilizing a high-quality transducer to ensure maximum ultrasound delivery to the treatment area. The output is a clean, culminated beam with the lowest available beam non-uniformity ratio
Study NCT06494553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy
Description: The Chattanooga Intelect ultrasound made in America. Year of production: 2013. It was clinically proven to provide the best possible treatment outcomes by utilizing a high-quality transducer to ensure maximum ultrasound delivery to the treatment area. The output is a clean, culminated beam with the lowest available beam non-uniformity ratio
Study NCT06494553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional treatment program
Description: US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors.
Study NCT06494553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment program
Description: US, IR and therapeutic exercise program that consisted of Stretching exercises included the following: 1) stretching pectoralis muscle, placing both hands on the occipital area and pulling the elbows back up, and performing arm abduction and external rotation. 2) Stretching the cervical extensors, placing both hands on the occipital area in a sitting position followed by a flexed neck posture with the head down to stretch the cervical extensors.
Study NCT05788432 — intervention group
Intervention type: DEVICE
Intervention: Sequent Please Neo
Description: Patients in whom treatment with (Sequent Please Neo) has been attempted
Study NCT06494553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared therapy
Description: Infrared therapy is a non-invasive treatment modality that uses infrared light to promote healing, reduce pain, and improve circulation. It involves the application of infrared light, which penetrates deep into the tissues, providing therapeutic benefits.
Study NCT06494553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared therapy
Description: Infrared therapy is a non-invasive treatment modality that uses infrared light to promote healing, reduce pain, and improve circulation. It involves the application of infrared light, which penetrates deep into the tissues, providing therapeutic benefits.
Study NCT05156073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: 1. Patient care partner cohort:~   a. mailing of an educational brochure introducing deprescribing to patients with mild cognitive impairment or dementia and/or MCC and MCC care partners.~2. Primary care physician cohort:~   1. education on deprescribing through a 15-45-minute presentation~  2. one-page weekly tip sheets on options for deprescribing in specific clinical situations and suggested language for deprescribing conversations.
Study NCT05120661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food product
Description: a food product containing 50 gram carbohydrates
Study NCT05951257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized multimodal intervention involving hypnosis and/or music
Description: The three intervention modalities (music and/or hypnosis) will begin by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself. The hypnosis modality consists in visiting in imagination a pleasant place that the participant will choose and to live some metaphorical stories. The musical modality consists of listening to one or two pieces of music chosen by each participant and which brings him/her well-being, according to them. These two types of work will be preceded by a moment of relaxation in which we will ask the participants to focus their attention on their breathing, on relaxation and on the process of absorption into oneself.
Study NCT06424834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.
Study NCT06424834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.
Study NCT06424834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once orally daily.